Aelis Farma

Aelis Farma is a clinical-stage biotech pioneering a new class of drugs called Signaling Specific inhibitors (CB1-SSi) that selectively block pathological signaling of the cannabinoid CB1 receptor without disrupting its normal function. Its lead asset, AEF0117, is in Phase 2b for cannabis use disorder, while its second candidate, AEF0217, is entering Phase 1/2 for cognitive deficits in Down syndrome. The company leverages a proprietary platform to generate new molecular entities and is supported by prestigious non-dilutive grants from the NIH and EU, positioning it at the frontier of neuropsychiatric pharmacology.

Proprietary platform for developing Signaling Specific inhibitors (SSi) of the cannabinoid CB1 receptor. These novel small molecules are designed to selectively inhibit pathological signaling pathways (e.g., from THC) while preserving the receptor's normal physiological functions, aiming to treat diseases without the side effects of full antagonists.

In cannabis use disorder, Aelis Farma's AEF0117 is a first-in-class pharmacological approach with a unique mechanism, facing limited direct competition. In cognitive disorders, the landscape is crowded, but AEF0217's targeted CB1 mechanism for specific conditions like Down syndrome could differentiate it from broader neuroactive drugs. The company's core competitive advantage is its proprietary platform for signaling-specific inhibition, a novel approach not widely replicated.